Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Ezra Cohen, MD, University of Chicago
First received: August 18, 2010
Last updated: September 6, 2012
Last verified: September 2012
The purpose of this study is to explore the activity of ZD1839 added to concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced head and neck cancer. Activity is described in terms of response rate (complete responses only).
Head and Neck Cancer
Drug: ZD 1839 500mg
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Ph II Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
Primary Outcome Measures:
Secondary Outcome Measures:
- Tolerability and Feasibility of ZD1839 [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
- To explore the tolerability and feasibility of ZD1839 added to concurrent chemoradiotherapy.
- To assess quality of life (QoL)
- To define any toxcities of ZD1839 used in concurrent chemoradiotherapy and as adjuvant therapy
• To assess pharmacodynamics of ZD1839 in vivo and correlate clinical outcome with inhibition of tyrosine kinase activity
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Primary Completion Date:
||May 2007 (Final data collection date for primary outcome measure)
Experimental: ZD1839 500mg by mouth (po) daily
Single arm, two-stage, phase II trial of induction therapy with carboplatin and paclitaxel, followed by ZD1839, 5-FU, hydroxyurea, and hyperfractionated radiotherapy, followed by adjuvant ZD1839 alone.
Drug: ZD 1839 500mg
Optional Induction chemotherapy:
Carboplatin and paclitaxel combination will be administered for 2 cycles of 4 weeks duration each. Paclitaxel: 100 mg/m2 in 500 ml of dextrose 5% in water over 3hrs. Carboplatin: Start after completion of paclitaxel on Day 1 AUC 6 (creatinine clearance [CC] + 25). Administered in 100 ml of normal saline over 30min after completion of paclitaxel.
Resume chemotherapy C2 on D29. ZD1839: 500mg PO QD from D1 of C1 of chemoradiotherapy, uninterrupted until disease progression. Chemotherapy should be administered during all 5 weeks of radiotherapy. P.M.:Start hydroxyurea at 500 mg PO q 12hrs × 6 days. The first daily dose of hydroxyurea on Days 1 through 5 is given 2 hours prior to the first fraction of daily radiotherapy. P.M.:Start continuous infusion of 5-FU at 600 mg/m2/day × 5D. Days 1 through 5: Radiation therapy is administered twice daily at 150 cGy ZD1839 will be administered from day 1 to 14 of every chemoradiotherapy cycle.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Histologically or cytologically confirmed diagnosis of squamous cell or poorly differentiated carcinomas, or lymphoepithelioma of the nasopharynx.
- Age 18 years or older.
- Patients with AJCC (6th edition, 2002) stage III or IV head and neck cancer.
- Patients with AJCC (6th edition, 2002) stage IV head and neck cancer. presenting with cervical lymph node metastasis of an unknown primary (i.e., TxN2 or TxN3) are also eligible.
- Prior to entry in the study, the resectability and alternative treatment options for each patient will be determined by a team composed of a head and neck surgeon, a radiation oncologist,and a medical oncologist. Stage determination, optimal local treatment, and its timing according to this protocol will be determined at this evaluation. Each patient will be classified as having resectable or unresectable disease. The unequivocal demonstration of distant metastasis (M1) confers ineligibility.
- Unidimensionally measurable disease (based on RECIST) is desirable but not strictly required. Individuals who are disease free at baseline after excisional biopsy or node dissection will be considered not evaluable for response assessment but are eligible.
- No prior or radiotherapy.
- Prior surgical therapy will consist only of incisional or excisional biopsy and organ-sparing procedures such as debulking of airway-compromising tumors or neck dissection in a patient with an unknown primary tumor.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%.
- Patients must have normal organ and marrow function as defined below absolute neutrophil count (ANC) ≥ 1,500/μl platelets ≥ 100,000/μl total bilirubin within normal institutional limits aspartate aminotransferase (AST, SGOT)/ alanine aminotransferase (ALT, SGPT) ≤ 2.5 × institutional upper limit of normal alkaline phosphatase ≤ 2 × upper limit of normal creatinine within normal institutional limits
- Unequivocal demonstration of metastatic disease (i.e. M1 disease).
- Known severe hypersensitivity to ZD1839 or any of the excipients of this product.
- Any coexisting malignancy that would increase risk of toxicity, interfere with interpretation of toxicity, or is associated with a median survival of less than 24 months.
- Concomitant use of phenytoin, carbamazepine, barbiturates, rifampin, phenobarbital, or St.John's Wort.
- Treatment with an investigational drug within 30 days before Day 1 of trial treatment.
- Incomplete healing from previous surgery.
- Pregnancy or breast feeding (women of child-bearing potential). Patients should be advised to use effective contraception as appropriate.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel, Cremaphor EL, carboplatin, 5 FU, or hydroxyurea.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection,symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any history of clinically significant CHF are excluded. The exclusion of patients with active coronary artery disease will be at the discretion of the attending physician.
- Patients must have no uncontrolled active infection other than that not curable without treatment of their cancer.
- No patients with severe baseline neurologic deficits (> grade II neuropathy) will be treated with induction chemotherapy.
- Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01185171
|The University of Chicago Medical Center
|Chicago, Illinois, United States, 60653 |
University of Chicago
||Ezra Cohen, MD
||The University of Chicago Medical Center
No publications provided
||Ezra Cohen, MD, Associate Prof of Medicine, University of Chicago
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 18, 2010
||September 6, 2012
||United States: Food and Drug Administration
Keywords provided by University of Chicago:
Oral Cavity and Pharynx
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 10, 2013
Head and Neck Neoplasms
Neoplasms by Site
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Antineoplastic Agents, Phytogenic
Protein Kinase Inhibitors